Brussels Team Expands with Experienced Competition Hire
Dr. Norbert Maier joins Cornerstone Research, with deep antitrust law and competition expertise from the EU Commission DG COMP team.
5 Questions with Sayeh Nikpay: The 340B Drug Pricing Program
Professor Sayeh Nikpay of the University of Minnesota discusses the role and implementation challenges of the 340B Drug Pricing Program.
Most-Favored Entry Clauses in Drug-Patent Litigation Settlements
The authors examine the competitive impacts of such clauses taking into account the regulatory structure and economics of the pharmaceutical industry in the United States.
Q&A with Joanna Tsai
WWL interviewed Joanna Tsai of Cornerstone Research about working at the FTC, the evolution of merger analysis, and her advice for aspiring competition economists.
The Global Antitrust Economics Conference
Rainer Schwabe and Anand Krishnamurthy will join competition experts to discuss the role of financial services and life sciences in antitrust.
Value Drug Company v. Takeda Pharmaceuticals U.S.A. Inc. et al.
Laurence Baker testified during a rare antitrust trial centering on the allegation that a brand manufacturer conspired with three generics to allocate the market for gout medication colchicine.
In re Novartis and Par Antitrust Litigation
Novartis reached settlements with plaintiffs in this reverse payment matter.
Cornerstone Research Staff and Affiliated Experts Submit Comments on the Joint FTC-DOJ Draft Merger Guidelines
The Federal Trade Commission and the Department of Justice’s Antitrust Division launched a joint public inquiry to solicit comments from the public on the draft updated merger guidelines.
Amgen Inc.’s Acquisition of Horizon Therapeutics plc
The FTC approves Amgen’s $28B purchase of Horizon.
The Economics of New Product Launches and Access to Pharmaceutical Products in the EU
The authors provide an economic perspective on the European Commission’s proposed reform of the EU’s pharmaceutical legislation.
In re HIV Antitrust Litigation
The jury found in favor of the defense concluding, consistent with Dr. Saravia’s testimony, that the settlement contained no payment for delay.
The Inflation Reduction Act Could Have Unintended Consequences
This article analyzes the potential unintended economic impacts of the Inflation Reduction Act on the pharmaceutical industry.
How can we help you?
If you are looking for a publication not on our website, contact us.